Pharmaceutical company Pfizer and German partner BioNTech announced Monday that they have reached an agreement to provide an additional 200 million doses of their coronavirus vaccine to the European Commission and EU Member States in 2022.
The two companies stressed that the 200 million installments will be added to the 450 million installments already scheduled to be delivered to the bloc countries, under previous agreements.
The new order “will also cover potential vaccines tailored to treat the Omicron variant at no additional cost if a variational vaccine is deemed necessary and then officially licensed,” the two companies said in a joint statement.
Pfizer shares rose 1.8% in pre-conference Wall Street trading, while BioNTech’s share “recorded” gains of more than 3%.
.
Source From: Capital

Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.